OncLive SOSS

Authors

Tami L. Thomas, PhD, CPNP, RNC, FAANP

Latest:

Promoting HPV Vaccination for Girls and Boys

Oncology nurses can lead the way in efforts to protect the next generation from this type of cancer if they know the facts about HPV vaccination for both girls and boys

Tanguy I. Seiwert, MD

Latest:

Dr. Seiwert on Managing Side Effects for Head and Neck Cancer Treatment

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.

Tanguy Seiwert, MD

Latest:

Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck Cancer

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

Tanguy Sewiert, MD

Latest:

Dr. Seiwert on Pembrolizumab in Head and Neck Cancer

Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.

Tanguy Y. Seiwert, MD

Latest:

Dr. Seiwert on Immunotherapy in Head and Neck Cancer

Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the impact of immunotherapy agents as treatment of patients with head and neck cancer.

Tanguy Y. Seiwert, MD, The University of Chicago Medical Center

Tania Jain, MBBS

Latest:

Dr Jain on Baseline Differences Across Different Donor Types in Myelofibrosis

Tania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.

Tanios Bekaii-Saab, MD

Latest:

Dr Bekaii-Saab on the Future of Treatment For Patients With GI Cancer

Tanios Bekaii-Saab, MD, FACP, discusses the future of treatment within the gastrointestinal cancers armamentarium.

Tanios Bekaii-Saab, MD, FACP

Latest:

Dr Bekaii-Saab on the Role of Liquid and Tissue Biopsies for Newly Diagnosed GI Cancers

Tanios Bekaii-Saab, MD, FACP, discusses the role of liquid and tissue biopsies in newly diagnosed gastrointestinal cancers.

Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

Latest:

Audience Q&A: Best Practices in Managing HER2-Amplified CRC

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

Tanios Bekaii-Saab, MD, Mayo Clinic

Latest:

Exciting Treatment Opportunities in mCRC

Closing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.

Tanios Bekaii-Saab, MD, Mayo Clinic Cancer Center in Arizona

Tanios Bekaii-Saab, MD, Ohio State University-James Cancer Hospital

Tanios Bekaii-Saab, MD, OSUCCC

Tanios Bekaii-Saab, MD, The Mayo Clinic

Tanios S. Bekaii-Saab, MD

Latest:

Novel Investigational Combination Strategies

Tanios S. Bekaii-Saab, MD, provides insight into ongoing research exploring novel combinations of tyrosine kinase inhibitors and immune checkpoint inhibitors across solid tumors.

Tanios S. Bekaii-Saab, MD, FACP

Latest:

Nivolumab plus Ipilimumab vs Chemotherapy as First-line Treatment for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: First Results of the CheckMate 8HW Study

In his discussion of the CHECKMATE 8HW trial, Dr. Tanios Bekaii-Saab examined the efficacy of chemotherapy versus nivolumab plus ipilimumab as the initial treatment for metastatic colorectal cancer with high microsatellite instability and deficient mismatch repair.